CORVERT Drug Patent Profile
✉ Email this page to a colleague
When do Corvert patents expire, and when can generic versions of Corvert launch?
Corvert is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in CORVERT is ibutilide fumarate. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ibutilide fumarate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Corvert
A generic version of CORVERT was approved as ibutilide fumarate by MYLAN INSTITUTIONAL on January 11th, 2010.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CORVERT?
- What are the global sales for CORVERT?
- What is Average Wholesale Price for CORVERT?
Summary for CORVERT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 71 |
| Clinical Trials: | 3 |
| Patent Applications: | 570 |
| Drug Prices: | Drug price information for CORVERT |
| What excipients (inactive ingredients) are in CORVERT? | CORVERT excipients list |
| DailyMed Link: | CORVERT at DailyMed |
Recent Clinical Trials for CORVERT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Cedars-Sinai Medical Center | Phase 4 |
| National Heart, Lung, and Blood Institute (NHLBI) | Phase 4 |
| Harvard University | Phase 4 |
Pharmacology for CORVERT
| Drug Class | Antiarrhythmic |
US Patents and Regulatory Information for CORVERT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | CORVERT | ibutilide fumarate | INJECTABLE;INJECTION | 020491-001 | Dec 28, 1995 | AP | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CORVERT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | CORVERT | ibutilide fumarate | INJECTABLE;INJECTION | 020491-001 | Dec 28, 1995 | ⤷ Subscribe | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CORVERT
See the table below for patents covering CORVERT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Hong Kong | 16192 | N-(AMINOALKYL-PHENYL)SULFONAMIDES THEIR PREPARATION AND THERAPEUTIC USE | ⤷ Subscribe |
| Japan | H0567620 | ⤷ Subscribe | |
| Germany | 3566886 | ⤷ Subscribe | |
| Mexico | 9203461 | N-(AMINOALQUILFENIL)SULFONAMIDAS SU PREPARACION Y USO TERAPEUTICO. | ⤷ Subscribe |
| Japan | S60239458 | NOVEL COMPOUND AND ANTIARRHYTHMIC MEDICINE COMPOSITION | ⤷ Subscribe |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CORVERT
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0164865 | SPC/GB97/003 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: IBUTILIDE, OR A PHARMACEUTICALLY-ACCEPTABLE SALT THEREOF, ESPECIALLY IBUTILIDE FUMARATE; REGISTERED: UK 00032/0212 19960930 |
| 0164865 | 97C0044 | Belgium | ⤷ Subscribe | PRODUCT NAME: IBUTILIDI FUMARAS (=IBUTILIDUM); NAT. REGISTRATION: 277 IS 253 F 12 19970617; FIRST REGISTRATION: GB PL 00032/0212 19960930 |
| 0164865 | C970030 | Netherlands | ⤷ Subscribe | PRODUCT NAME: IBUTILIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARD BAAR ZOUT, IN HET BIJZONDER HET FUMARAAT; NAT. REGISTRATION NO/DATE: RVG 21286 19970612; FIRST REGISTRATION: GB PL 0032/0212 19960930 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
